The product nomenclature consolidates a lipophilic phenolic active pharmaceutical ingredient, 2,6-diisopropylphenol, with downstream use in injectable oil-in-water emulsion dosage forms. The pure API carries CAS 2078-54-8, molecular formula C₁₂H₁₈O, and molar mass 178.27 g/mol. At controlled room temperature, neat propofol exists near the boundary of liquid and crystalline-solid states; melting point is reported near 18 °C. The molecule is a weak acid with a pKa near 11, and its partition coefficient log P is approximately 3.8, which accounts for negligible aqueous solubility—generally below 1 g/L at 25 °C—and for ready partitioning into soybean oil or medium-chain triglyceride vehicle phases. Pharmacopeial-grade API is supplied in amber glass or fluoropolymer-lined containers under inert headspace because phenolic oxidation produces quinone and dimeric degradation products. The product model family includes finished injectable emulsions at 10 mg/mL (1% w/v) and 20 mg/mL (2% w/v), with the label designation defining the intended concentration in an oil-in-water emulsion for intravenous administration. For solid oral dosage forms listed in the commercial title—tablet, capsule, granule—the unmodified API cannot be directly compressed or encapsulated without first addressing a melting point below typical dry-granulation die temperatures and an oral first-pass extraction that substantially reduces systemic availability.

What Limits Oral Administration of the Unmodified Phenolic API?

Oral delivery of propofol is constrained primarily by hepatic first-pass metabolism, not by an absence of activity at the gamma-aminobutyric acid type A receptor. Propofol blood clearance in adults ranges from approximately 1.5 L/min to 2.2 L/min, approaching liver blood flow, and published data for human oral bioavailability of the unmodified phenolic API are limited and highly variable. A tablet or capsule containing the neat phenolic API would also encounter poor powder flow, low melting-derived tack, and oxidative instability in the presence of standard tableting lubricants. The term “oral” in the product description is therefore best interpreted as compatibility with lipid-based formulation precursors or softgel development, not as a validated monographed oral dosage form. For a softgel or self-emulsifying system, the API can be dissolved in medium-chain triglycerides and combined with surfactants having hydrophilic-lipophilic balance values above 10, but no USP or Ph. Eur. monograph currently defines acceptable impurity limits or dissolution criteria for a solid oral propofol finished product.

Finished propofol injectable emulsion is an oil-in-water dispersion with a continuous aqueous phase adjusted to pH 7.0–8.5. The dispersed oil phase is typically refined soybean oil at 100 mg/mL in the 1% product; purified egg lecithin at approximately 12 mg/mL functions as the interfacial phospholipid, and glycerol at 22.5 mg/mL contributes to tonicity. The emulsion is not a solution, and its white appearance arises from light scattering by submicron oil droplets. The product is terminally sterilized by autoclaving, and the formulation must survive thermal stress without phase separation, free-oil creaming, or mean droplet growth beyond the limits measured by USP <729> or Ph. Eur. 2.9.50. On production-scale lines, rotor-stator premixing followed by high-pressure homogenization at 800–1,200 bar is used to achieve a mean droplet diameter below 500 nm; batch-to-batch variance is lowest when the aqueous phase is preheated to 50–60 °C and the lipid phase to 60–70 °C before emulsification. Droplet size excursions above 5 µm are critical because the terminal filter on intravenous sets does not retain dispersed lipid globules in the same manner as a true solution, and large-diameter tail populations are associated with reduced emulsion stability. USP <729> Method II reports the volume-weighted percentage of fat greater than 5 µm, with a threshold commonly set at 0.05 % for injectable lipid emulsions.

On a typical high-shear mixing line, the aqueous phase is prepared with glycerol and sodium hydroxide to a target pH, while the lipid phase is prepared with soybean oil and lecithin at elevated temperature. After rotor-stator premixing, the coarse emulsion is passed through a high-pressure homogenizer. Batch cooling is performed immediately after homogenization; holding the emulsion at 70 °C for more than 60 min accelerates lecithin hydrolysis and increases free fatty acid content, which reduces zeta potential and promotes droplet coalescence. The finished bulk is then filled into glass vials or ampoules under nitrogen. Terminal sterilization at 121 °C for 15 min is typical, although the exact overkill cycle is batch-size dependent. Post-sterilization droplet-size testing is mandatory because autoclaving can increase mean droplet diameter and widen the large-diameter tail. Production batches that fail USP <729> PFAT5 are not reprocessable by simple re-homogenization after filling, because reheating an already-sterile emulsion to homogenization temperature breaches the thermal history of the lipid phase and increases oxidation byproducts.

Specification Matrix and Pharmacopeial Alignment

Release testing for pharma-grade propofol API follows the Propofol monograph of the current USP/NF and the corresponding Ph. Eur. monograph. Identification is confirmed by infrared absorption spectrophotometry and retention time in a validated liquid chromatographic procedure. Assay by HPLC is typically controlled within 98.0–102.0 % on the anhydrous, solvent-free basis. Related substances are monitored for specified oxidation products including quinone and nitrosophenol derivatives; total impurities are commonly controlled below 0.3 %. Residual solvents, sulfated ash, heavy metals, and water content are tested according to the corresponding general chapters. Because the API is a liquid near room temperature, water content by Karl Fischer titration uses a solubility-enhancing solvent mixture, and the filled container must be sampled under nitrogen to avoid atmospheric oxidation.

Comparison with midazolam, etomidate, and fospropofol highlights distinct formulation and handling boundaries. Midazolam is water-soluble at acidic pH due to benzodiazepine ring protonation and is filled as a true solution, allowing dilution in common crystalloid solutions; propofol emulsion cannot be diluted indefinitely without risking creaming and lipid particle enlargement. Etomidate is supplied in a propylene glycol solution or a lipid emulsion; the adrenal-suppressive effect after continuous infusion is not present with propofol. Fospropofol is a phosphate ester prodrug that is water-soluble before in vivo alkaline phosphatase cleavage; its onset is slower and it carries a lower lipid load per dose, but it is not equivalent to propofol in deep sedation onset. Within the propofol product class, 2% emulsion reduces the infused volume and lipid burden per milligram of active drug relative to 1% emulsion, but the higher dispersed-phase mass can increase emulsion instability if mixed with lidocaine or acidic additives.

When the Same API Is Supplied for Non-Emulsion Compounding Workflows

When the same pharma-grade API is considered for tablet, capsule, or granule intermediate development, the formulator must specify whether the material is a free-flowing liquid, a solidified bulk stored below 18 °C, or a spray-dried or adsorbed intermediate. Compressing freeze-chilled propofol with microcrystalline cellulose and croscarmellose sodium is not a standard operation because the API plasticizes under compression pressure above 50 MPa. Dry granulation by roller compaction is limited by melting and sticking at roller surface temperatures above 20 °C, and wet granulation requires a non-aqueous binder system because water solubility is below 1 g/L. In capsule filling, hard gelatin shells are incompatible with the neat liquid unless the API is pre-adsorbed onto colloidal silicon dioxide or formulated as a semisolid lipid matrix. Published data for solid oral dosage forms of unmodified propofol in current compendial frameworks are limited, so development work is governed by ICH Q8 quality-by-design principles and product-specific stability protocols.

Oxidative degradation of propofol API is propagated by light, oxygen, and trace transition metals. The primary degradants include 2,6-diisopropyl-1,4-benzoquinone and related nitrosophenol species; these are monitored by HPLC with UV detection in the range of 254–270 nm. Long-term stability of the API in original containers is typically assigned a retest interval of 24 months at 2–8 °C; stressed stability studies at 40 °C and 75 % relative humidity are used to bracket tropical distribution environments. The finished injectable emulsion is stored at 4–25 °C and should not be frozen; freezing produces ice crystals that rupture the interfacial phospholipid film and cause immediate coalescence and oil separation on thawing.

Finished propofol injectable emulsions differ between manufacturers in preservative strategy, oil source, lecithin origin, and package closure. Some formulations contain disodium edetate at 0.005 % w/v to suppress microbial growth, while others are preservative-free. Products using medium-chain triglycerides or blends of medium- and long-chain triglycerides have lower viscosity and lower free fatty acid load; these differences alter syringeability, pain on injection, and stability in certain admixtures. The prescriber-facing label concentration remains 10 mg/mL or 20 mg/mL, but the inactive-ingredient profile is not interchangeable in patients with soy, egg, or lipid sensitivities. Published comparative data show that generic 1% emulsions may differ in the incidence of injection pain when the aqueous-phase free propofol concentration is raised by pH or formulation differences; this variable is controlled by maintaining the emulsion pH at the upper end of the 7.0–8.5 range as much as stability permits.

Propofol injectable emulsion is commonly diluted with 5% Dextrose Injection, USP, but not with Lactated Ringer’s Injection in a single infusion container, because the higher ionic strength and calcium content can destabilize the phospholipid-stabilized interface. If lidocaine is used to reduce pain on injection, the addition should not exceed 20 mg of lidocaine hydrochloride per 200 mg of propofol, and the mixture should be used immediately because lidocaine lowers emulsion pH and may accelerate droplet growth. Administration through a 0.22 µm sterilizing filter is not recommended for the emulsion; validated infusion sets with a suitable porosity and minimal PVC contact are used. Long-duration infusion through unlined PVC tubing can extract di(2-ethylhexyl) phthalate from the tubing. The finished injectable emulsion is single-use and should be handled according to aseptic technique under USP <797> when drawn into syringes. An opened vial or drawn syringe should be used within 6 h because preservative-free formulations support the growth of Gram-positive and Gram-negative organisms if contaminated.